DUBAI (Reuters) – Emirati national investment firm APEX signed an “industry strategic agreement” with Tera Group of Israel to cooperate on studies and progression similar to COVID-19, adding a device, UAE official news agency WAM said Saturday.
The agreement “is seen as the first company to open up trade, the economy and effective partnerships between the Emirati and Israeli trade sectors, to gain the benefits of humanity by strengthening studies and studies on the new coronavirus,” said APEX President Khalifa Yousef Khoury. Training
The agreement signed at a press convention in Abu Dhabi, shortly after Israel and the United Arab Emirates announced on Thursday an agreement that will lead to a whole normalization of diplomatic relations between the two states.
“The United Arab Emirates and Israel will without delay expand and boost cooperation on the remedy and progression of a coronavirus vaccine,” the two countries said as a whole on Thursday.
U.S. President Donald Trump helped negotiate the deal, which Israel agreed to suspend its planned annexation of spaces in the occupied West Bank.
The delegations of Israel and the United Arab Emirates will meet in the coming weeks to signal agreements on investment, tourism, direct flights, security, telecommunications and other issues, the whole said.
“TeraGroup’s biosecurity testing is taking place in some countries around the world, adding Emirates Field Hospital in Abu Dhabi, with plans to make all UAE bigger,” WAM said.
In June, the United Arab Emirates said two personal corporations in the United Arab Emirates and two Israeli corporations would work together on medical projects, contributing to the fight against the new coronavirus.
In July, two state-owned Israeli defense contractors announced partnerships with Abu Dhabi-based Group 42 generation corporate to expand technologies to combat the new coronavirus.
Reporting through Nayera Abdallah; Written through Nafisa Eltahir; Editing through Daniel Wallis
All quotes were delayed for at least 15 minutes. See here for a complete list of transactions and delays.
© 2020 Reuters. All rights are reserved.